

DAFTAR PUSTAKA

1. **Manuaba TW (ed).** Panduan Penatalaksanaan Kanker Solid PERABOI 2010. CV Sagung Seto, Jakarta. 2010
2. **Taghian A, El Ghamry, Merajver SD.** Overview the treatment of newly diagnosed, non metastatic breast cancer, www.uptodate.com, July 2016
3. **Yalcin.** Overview on locally advanced breast cancer: definition, epidemiology and overview on neoajuvant therapy, *Experimental Oncology* 2013 vol 35
4. **Hohenberger P, Horiot JC, Souhami RL, Tannock I.** Oxford textbook of oncology 2nd ed: Treatment of breast cancer. Oxford Press, February, 2010
5. **Anders CK, Carey LA, Hayes DF et al.** Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2 negative (triple negatif) breast cancer, www.uptodate.com, July 2016
6. **Trivers KF, Lund MJ et al.** The epidemiology of triple negatif breast cancer, including race, *Cancer Causes Control* no 20:1071-1082, Springer Pub Juni 2014
7. **Loi S, Michiels S, Salgado R et al.** Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol* 2014; 25(8): 1544-1550.
8. **Loi S, Sirtaine N, Piette F et al.** Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol* 2013; 31: 860-867.
9. **Adams S, Demaria S, Goldstein L et al.** Prognostic value of tumor-infiltrating lymphocytes (TIL) in Triple negatif Breast Cancers (TNBC) from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol* 2014 Jul 28 [epub ahead of print], doi: JCO.2013.55.0491.

10. **Proietti E, Moschella F, Capone I, Belardelli F.** Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. *Mol Oncol* 2012; 6: 1-14
11. **John Stagg Fabrice Andre Sherene Loi.** Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? *Breast Care* 2012;7:267-272
12. **Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesnière A, Kroemer G.** The anticancer immune response: indispensable for therapeutic success? *J Clin Invest* 2008;118:1991-2001
13. **Gu-Trantien C et al.** CD4+ follicular helper T-cell infiltration predicts breast cancer survival. *J Clin Invest* 123:2873-2882, 2013
14. **West N et al.** Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. *Breast Cancer Research* 2011
15. **Salgado R, Denkert C, Sirtaine N et al.** The evaluation of tumor infiltrating lymphocytes (TIL) in breast cancer: recommendation by an international TIL working group 2014. *Annals of Oncology* 26:259-271, 2015
16. **Savas P, Salgado R, Denkert C, et al.** Clinical relevance of host immunity in breast cancer: from TIL to the clinic. *Nature Rev in Clin Oncol.* published on line 15 Dec 2015.
17. **Mittal D, Gubin MM, Schreider RD and Smyth MJ.** New insight into cancer immunoeediting an its three component phases-elimination, equilibrium and *escape*. *Current opinion in Immunology* no 27:16-25, Elsevier 2014
18. **Galluzzi L et al.** Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents, *Riview Cancer Cell*, Elsevier Inc, 2015
19. **Disis ML, Stanton SE.** Triple-Negative Breast Cancer: Immune Modulation us the New Treatment Paradigm. 2015 ASCO Educational Book. Asco.org/edbook.
20. **Denkert C, Loibl S, Noske A, et al.** Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol.* 2010; 28:105-3.

21. **Bracci, G Schiavoni, A Sistigu and F Belardelli.** Review Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , *Cell Death and Differentiation* 21, 15–25, Macmillan publishers limited 2012.
22. **Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME .** Lymphocyte depletion during treatment with intensive chemotherapy for cancer. *Blood* 1994; 84: 2221–2228.
23. **Wijayabadi N, Haron MR, Stauslas J, Yusuf Z.** Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline rejimens. *J Chemother* 2007;19: 716–723.
24. **Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC.** The DNA damage response induces IFN. *J Immunol* 2011; 187: 5336–5345.
25. **Zhang Z et al** Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy. *Cancer letters*, Elsevier 2015
26. **Simosa DC, Ginsburg M, Ophira.** Definition and consequences of locally advanced breast cancer. *Lipincot and Wilkins Vol 8 number 1* ,2014
27. **Gonzalez AM, Hortobagyi GN.** Inflammatory and locally advanced breast cancer. *Springer-Verlag* 2010
28. **ESO-ESMO.** 2nd international concensus guidelines for advanced breast cancer 2014
29. **Bunstein MD, Tsimelzon A, Poage GM, et al.** Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clinical Cancer Res.* 2015; 21:1688–98)
30. **Lehman BD, Bauer JA, Chen X, et al.** Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Clin Invest.* 2011; 121 (7) :2750–67
31. **Rustogi A et al .** Management of locally advanced breast cancer: evolution and curent practice. *J Cancer Res Cher*, march 2011
32. **Khokher S, Quereshi MU, Chaundry NA.** Comparison of WHO and RECIST criteria for evaluation clinical response for chemotherapy in patient with advanced breast cancer , *Asian pasific Journal of Cancer Prevention* 2012

33. **Eisenhauer EA et al.** New response evaluation criteria in solid tumor:revised RECIST guideline (version 1.1), *European Journal of cancer* no 45, 2010
34. **Kashiwagi S et al.**Use of tumor infiltrating lymphocytes (TIL) to predict the treatment response to eribulin chemotherapy in breast cancer. *PLOS Journal*,Oktober 2016
35. **Jana Pahole et al.** Prognostic value of routinely determined tumor infiltrating lymphocytes in triple-negative breast cancer *Journal of Clinical Oncology* 2015
36. **Sethi D et al.** Histopathologic change following neoadjuvant chemoteraphy in locally advanced breast cancer , *Indian Journal of Cancer* januari-march vol 50 2013
37. **Valagussa et al.**T3b-T4 factors affecting result in combined modality treatment *Clin Exp metastasis* 1983 p 191-202
38. **Sander Muhammad.**Profil penderita kanker payudara stadium lanjut baik lokal maupun metastasis jauh di RSUP Hasan Sadikin Bandung,2015
39. **Carter et al.** Relation of tumor size,lymp node status and survival in 24,740 breast cancer case .*cancer* 1989:63:181-187
40. **Memon ZA et al.** Reason for patient's delay in diagnosis of breast carcinoma in Pakistan, *Asian Pac J Cancer Prev* 2013
41. **De ruijter et al.** Characteristic of triple negative breast cancer, *J cancer Res Clin Oncol* 2011
42. **Eunjung lee et al.**Characteristics of triple negative breast cancer in patient with a BRCA1 mutation:result from a population-based study of young woman,*Journal of clinical oncology*,2011
43. **Bontenhal et al.**EORTC breast cancer cooperative group,doxorubicin vs epirubicin report of a second line randomized phase II/III study in advanced breast cancer,*British Journal of Cancer* 77 : 1257-2263,1998
44. **Stanton et al.**Variation in the incidence and magnitude of tumor infiltrating lymphocytes in breast cancer subtype : A systematic review,*Jama Oncol* 2016

45. **Zhang et al.** Prognostic and predictive value of tumor infiltrating lymphocytes in breast cancer: a systematic review and meta analysis, *Clin Transl Oncol* 18:949-506 , 2016
46. **Chen WC, Lai YH, Chen HY et al.** Interleukine 17 producing cell infiltration in breast cancer micro environment is a poor prognostic factor, *Histopathology* 63(2) 225-13 .2013
47. **May Adjuman S et al.** Anti cancer chemotherapy induced intratumoral recruitment and different factor of antigen presenting cell, *Immunity* 38(4) 729-41 .2013